Key Account Management Europe Summit

eyeforpharma29 - 30 November 2010, London, UK.
eyeforpharma's Key Account Management Europe Summit, taking place in London in November, includes a half-day workshop led by David Wright, director of Imonic, a leading expert on KAM and chair of the KAM stream at SFE Europe 2010 in Barcelona. Following the success of the SFE event, which attracted over 200 delegates to the KAM element alone, David's detailed discussions with Kate Eversole and eyeforpharma contributed to the formulation of the new London-based KAM summit, which we are delighted to see includes an impressive program of speakers from both pharma and healthcare providers.

The November workshop will focus on providing practical solutions, and will address in particular the following:

  • How to get and keep commitment from your leadership team, not just a token lip-service acceptance (e.g., comments such as "You can implement KAM but you can't change the organizational structure or the incentive scheme, and we're not investing in new IT systems!"). How do you prove that the ‘old model' is broken and no longer works? How do you exploit and communicate the benefits of KAM and get the investments and commitments you need to make a success of KAM in your organization?
  • How to measure KAM effectively. The temptation is to still track 'calls per day', but the emphasis with KAM is on quality, not quantity, so other metrics become relevant. What are these metrics? How do they correlate to sales and how can they be implemented?
  • Why is effective planning critical to the success of KAM? How do you get the balance right between time allocated to planning and time in the field? What constitutes best practice as far as planning is concerned, and how can effective account strategies be developed and implemented?
  • How to align IT systems to support best practice in KAM and how to develop a clear statement of requirements and assess the gaps.
  • What are the account management skills critical for KAM success? How do we achieve a high quality of engagement from account teams?
  • How to use a customer feedback program to improve success with KAM and identify what customers want and evaluate their feedback.

Imonic's David Wright will offer unique insights into how pharma should confront these challenges in 2011, with practical advice and solutions based on Imonic's experiences of KAM implementation in pharma and for over 20 years in other sectors.

For further information and registration, please visit:
http://www.eyeforpharma.com/kameu/

About eyeforpharma
eyeforpharma is a division of a private company headquartered in London, UK. We have offices in New York, South Africa and Australia. We have grown by at least 30% per year since our creation in 2002.

We are the sum of the quality of those people and pride ourselves on recruiting not only the professional and innovative but the personable. That is why so many of our contacts are now our friends aswell as our trusted advisors. It is this level of dialogue that we seek to promote throughout the pharma world.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...